…an overall survival (OS) advantage was seen with the Opdivo plus Yervoy combination over sunitinib in both the PD-L1 expression level <1% [HR= 0.73, (CI: 95% 0.56 to 0.96)] and ≥1% subgroups [HR= 0.45 (CI: 95% 0.29 to 0.71)].
The median overall survival (OS) was not reached for the Opdivo plus Yervoy combination or sunitinib for those with PD-L1 levels < 1%, and for patients with PD-L1 expression levels ≥1%, the median OS was not reached for the combination and was 19.6 months for sunitinib.
CHECKPOINT-214 was stopped early for OS success in Sep 2017 (#msg-134437412), but the details were not disclosed until now.
CHECKPOINT-214 tested Opdivo+Yervoy vs Sutent and had three co-primary endpoints: ORR, PFS, and OS. In Aug 2017, BMY reported that the trial hit the ORR endpoint and missed on PFS (#msg-133869270).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.